<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02036970</url>
  </required_header>
  <id_info>
    <org_study_id>RTA 402-C-1302</org_study_id>
    <nct_id>NCT02036970</nct_id>
  </id_info>
  <brief_title>Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT</brief_title>
  <official_title>A Dose-Ranging Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Reata Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Reata Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study assesses the safety and efficacy of bardoxolone methyl relative to placebo in
      patients with pulmonary hypertension to determine the recommended dose range, evaluate the
      change from baseline in 6-minute walk distance (6MWD) and determine the effect of Bardoxolone
      methyl in pulmonary hypertension associated with connective tissue disease, interstitial lung
      disease, and idiopathic etiologies, including subsets of patients with WHO Group III or WHO
      Group V PH following 16 weeks of study participation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The molecular and pharmacological effects of bardoxolone methyl are broad through its
      induction of Nrf2 and suppression of NF-κB. Bardoxolone methyl may therefore address multiple
      facets of the pathophysiology of PH because it suppresses activation of proinflammatory
      mediators, enhances endothelial NO bioavailability, improves metabolic dysfunction,
      suppresses vascular proliferation, and prevents maladaptive remodeling. Furthermore, while
      existing therapies primarily target only smooth muscle cells, bardoxolone methyl targets
      multiple cell types relevant to PH, including endothelial cells, smooth muscle cells, and
      macrophages.

      This is a two-part study.

      Part 1: Part 1 of the study will include a dose-ranging phase and a dose-titration phase.

      Part 2 (extension period): All patients from Part 1 who complete the 16-week treatment period
      as planned will be eligible to continue directly into the extension period to evaluate the
      intermediate and long-term safety and efficacy of bardoxolone methyl.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Actual">January 19, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in 6-Minute Walk Distance (6MWD)</measure>
    <time_frame>16 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">166</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <condition>Pulmonary Hypertension</condition>
  <condition>Interstitial Lung Disease</condition>
  <condition>Idiopathic Interstitial Pneumonia</condition>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <condition>Sarcoidosis</condition>
  <condition>Respiratory Bronchiolitis Associated Interstitial Lung Disease</condition>
  <condition>Desquamative Interstitial Pneumonia</condition>
  <condition>Cryptogenic Organizing Pneumonia</condition>
  <condition>Acute Interstitial Pneumonitis</condition>
  <condition>Idiopathic Lymphoid Interstitial Pneumonia</condition>
  <condition>Idiopathic Pleuroparenchymal Fibroelastosis</condition>
  <arm_group>
    <arm_group_label>Dose-Ranging Phase: Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bardoxolone methyl [Dose 1] mg capsules or placebo by mouth once daily x 16 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose-Ranging Phase: Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bardoxolone methyl [Dose 2] mg capsules or placebo by mouth once daily x 16 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose-Ranging Phase: Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bardoxolone methyl [Dose 3] mg capsules or placebo by mouth once daily x 16 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose-Ranging Phase: Dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bardoxolone methyl [Dose 4] mg capsules or placebo by mouth once daily x 16 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose-Titration Phase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bardoxolone methyl [Dose 2] mg capsules or placebo by mouth once daily x 3 weeks, escalating to [Dose 3] mg or placebo by mouth once daily at Week 4 for 13 weeks
If a patient experiences a dose-limiting toxicity, the investigator may de-escalate the dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bardoxolone methyl</intervention_name>
    <arm_group_label>Dose-Ranging Phase: Dose 1</arm_group_label>
    <arm_group_label>Dose-Ranging Phase: Dose 2</arm_group_label>
    <arm_group_label>Dose-Ranging Phase: Dose 3</arm_group_label>
    <arm_group_label>Dose-Ranging Phase: Dose 4</arm_group_label>
    <arm_group_label>Dose-Titration Phase</arm_group_label>
    <other_name>RTA 402 capsules</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Dose-Ranging Phase: Dose 1</arm_group_label>
    <arm_group_label>Dose-Ranging Phase: Dose 2</arm_group_label>
    <arm_group_label>Dose-Ranging Phase: Dose 3</arm_group_label>
    <arm_group_label>Dose-Ranging Phase: Dose 4</arm_group_label>
    <arm_group_label>Dose-Titration Phase</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult male and female patients ≥ 18 to ≤ 75 years of age upon study consent;

          2. BMI &gt; 18.5 kg/m²

          3. Symptomatic pulmonary hypertension WHO class II and III;

          4. WHO Group I, III, or V PH according to the following criteria:

               1. If diagnosed with WHO Group I PAH, then on of the following subtypes:

                    -  Idiopathic or heritable PAH;

                    -  PAH associated with connective tissue disease;

                    -  PAH associated with simple, congenital systemic-to-pulmonary shunts at least
                       1 year following shunt repair;

                    -  PAH associated with anorexigen or drug-induced toxicity;

                    -  PAH associated with human immunodeficiency virus (HIV); or

               2. If WHO Group III PH then primary diagnosis must be one of the following subtypes:

                    -  Connective tissue disease associated ILD (CTD-ILD);

                    -  Idiopathic pulmonary fibrosis (IPF);

                    -  Nonspecific interstitial pneumonia (NSIP); or

               3. If WHO Group V PH then patient must be diagnosed with sarcoidosis;

          5. Had a diagnostic right heart catheterization performed and documented within 36 months
             prior to Day 1 that confirmed a diagnosis of PH

          6. If WHO Group I, has been receiving no more than three (3) FDA-approved
             disease-specific PAH therapies except for intravenous (iv) prostacyclin/prostacyclin
             analogues. PAH therapy must be at a stable dose for at least 90 days prior to Day 1;

          7. Has adequate kidney function defined as an estimated glomerular filtration rate (eGFR)
             ≥ 45 mL/min/1.73 m2 using the Modification of Diet in Renal Disease (MDRD) 4-variable
             formula;

        Exclusion Criteria:

          1. Participation in other interventional clinical studies involving pharmaceutical
             products being tested or used in a way different from the approved form or when used
             for an unapproved indication within 30 days prior to Day 1;

          2. Initiation of an exercise program for cardio-pulmonary rehabilitation within 3 months
             (90 days) prior to Day 1 or planned initiation during Part 1 of the study;

          3. Stopped receiving any PH chronic therapy within 60 days prior to Day 1;

          4. Requirement for receipt of intravenous inotropes within 30 days prior to Day 1;

          5. Has uncontrolled systemic hypertension as evidenced by sitting systolic blood pressure
             (BP) &gt; 160 mm Hg or sitting diastolic blood pressure &gt; 100 mm Hg during Screening
             after a period of rest;

          6. Has systolic BP &lt; 90 mm Hg during Screening after a period of rest;

          7. WHO Group III or V patients who at rest require supplemental oxygen at a rate of &gt;4
             L/min and have peripheral capillary oxygen saturation levels &lt;92%;

          8. Has a history of clinically significant left-sided heart disease and/or clinically
             significant cardiac disease,including but not limited to any of the following:

               1. Congenital or acquired valvular disease if clinically significant apart from
                  tricuspid valvular insufficiency due to pulmonary hypertension;

               2. Pericardial constriction;

               3. Restrictive or congestive cardiomyopathy;

               4. Left ventricular ejection fraction &lt; 40% per echocardiogram (ECHO) within 60 days
                  of Day 1;

               5. Any current or prior history of symptomatic coronary disease (prior myocardial
                  infarction, percutaneous coronary intervention, coronary artery bypass graft
                  surgery, or anginal chest pain);

          9. Acutely decompensated heart failure within 30 days prior to Day 1, as per Investigator
             assessment;

         10. History of atrial septostomy within 180 days prior to Day 1;

         11. History of obstructive sleep apnea that is untreated;

         12. Has a history of portal hypertension or chronic liver disease, including hepatitis B
             and/or hepatitis C (with evidence of recent infection and/or active virus replication)
             defined as mild to severe hepatic impairment (Child-Pugh Class A-C);

         13. Serum aminotransferase (ALT or AST) levels &gt; the upper limit of normal (ULN) at
             Screening;

         14. For patients with HIV-associated PAH, any of the following:

               1. Concomitant active opportunistic infections within 180 days prior to Screening;

               2. Detectable viral load within 90 days prior to Screening;

               3. Cluster designation (CD+) T-cell count &lt; 200 mm3 within 90 days prior to
                  Screening;

               4. Changes in antiretroviral regimen within 90 days prior to Screening;

               5. Using inhaled pentamidine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Banner University Medical Center, Phoenix Advanced Lung Disease Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Pulmonary Specialists</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedars Sinai Medical Center</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Healthcare System of Greater Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Davis Medical Center - Division of Pulmonary and Critical Care</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harbor - UCLA Medical Center</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Denver - Division of Pulmonary Sciences</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Denver Cardiology Associates, P.C</name>
      <address>
        <city>Littleton</city>
        <state>Colorado</state>
        <zip>80120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown University Medical Center - Department of Rheumatology</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic of Florida</name>
      <address>
        <city>Weston</city>
        <state>Florida</state>
        <zip>33331</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maine Medical Center - Division of Pulmonary and Critical Care Medicine</name>
      <address>
        <city>Portland</city>
        <state>Maine</state>
        <zip>04102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston University School of Medicine</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winthrop University Hospital</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <zip>11501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai, Beth Israel Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester - University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Lindner Clinical Trial Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati - Department of Internal Medicine Pulmonary, Critical Care &amp; Sleep Medicine</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma Heart Hospital</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BreatheAmerica El Paso, Inc.</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Research Institute</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Texas - Health Science Center &amp; Medical School at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Houston - Division of Rheumatology and Clinical Immunogenetics</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinic Carl Gustav Carus</name>
      <address>
        <city>Dresden</city>
        <zip>01304</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Spain</country>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 13, 2014</study_first_submitted>
  <study_first_submitted_qc>January 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2014</study_first_posted>
  <last_update_submitted>April 2, 2018</last_update_submitted>
  <last_update_submitted_qc>April 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pulmonary Arterial Hypertension</keyword>
  <keyword>PAH</keyword>
  <keyword>Bardoxolone methyl</keyword>
  <keyword>6-minute walk distance</keyword>
  <keyword>CDDO-me</keyword>
  <keyword>RTA 402</keyword>
  <keyword>Pulmonary Hypertension</keyword>
  <keyword>Interstitial Lung Disease</keyword>
  <keyword>Idiopathic Interstitial Pneumonia</keyword>
  <keyword>Idiopathic Pulmonary Fibrosis</keyword>
  <keyword>Sarcoidosis</keyword>
  <keyword>Respiratory Bronchiolitis Associated ILD</keyword>
  <keyword>Desquamative Interstitial Pneumonia</keyword>
  <keyword>Cryptogenic Organizing Pneumonia</keyword>
  <keyword>Acute Interstitial Pneumonitis</keyword>
  <keyword>Idiopathic Lymphoid Interstitial Pneumonia</keyword>
  <keyword>Idiopathic Pleuroparenchymal Fibroelastosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Bronchiolitis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
    <mesh_term>Sarcoidosis</mesh_term>
    <mesh_term>Lung Diseases, Interstitial</mesh_term>
    <mesh_term>Genetic Diseases, Inborn</mesh_term>
    <mesh_term>Cryptogenic Organizing Pneumonia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

